Tirzepatide Dosage Chart: Mounjaro and Zepbound Dosing Guide

Key Takeaways

• Both Mounjaro and Zepbound start at 2.5 mg once weekly, with dose increases in 2.5 mg steps no more often than every 4 weeks.

• Mounjaro and Zepbound contain tirzepatide but have different FDA-approved indications and should not be treated as identical dosing programs.

• Maximum Mounjaro dose: 15 mg once weekly in adults and 10 mg once weekly in pediatric patients age 10 years and older.

• Zepbound maintenance doses: 5 mg, 10 mg, or 15 mg for chronic weight management; 10 mg or 15 mg for obstructive sleep apnea.

• There is no universal tirzepatide dosage-in-units chart for compounded products because syringe units depend on the product concentration.

Tirzepatide: What Is It?

Tirzepatide is a dual GIP and GLP-1 receptor agonist marketed in the United States as Mounjaro and Zepbound. The same active ingredient is used under different brand indications.

Mounjaro is approved to improve glycemic control in adults and children age 10 years and older with type 2 diabetes. The August 2026 label also includes reduction of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events.

Zepbound is approved with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity.

Tirzepatide Dosage Chart

The general escalation pattern starts at 2.5 mg once weekly and increases in 2.5 mg steps after at least 4 weeks on the current dose. The correct maintenance dose depends on the brand, indication, age, response, and tolerability.

Source: Mounjaro Prescribing Information and Zepbound Prescribing Information.

Mounjaro Dosage for Adults With Type 2 Diabetes

Mounjaro starts at 2.5 mg once weekly. If additional glycemic control is needed, the dose may be increased by 2.5 mg after at least 4 weeks on the current dose. The maximum adult dose is 15 mg once weekly.

The current Mounjaro label does not provide a separate cardiovascular-only dosing schedule; the standard Mounjaro dosing framework is used.

Mounjaro Dosage for Children Age 10 and Older

For pediatric patients age 10 years and older with type 2 diabetes, Mounjaro starts at 2.5 mg once weekly. If additional glycemic control is needed, the dose may be increased by 2.5 mg after at least 4 weeks on the current dose. The maximum pediatric dose is 10 mg once weekly.

Zepbound Dosage for Weight Management

Zepbound starts at 2.5 mg once weekly for 4 weeks. The 2.5 mg dose is for treatment initiation and is not an approved maintenance dose. After 4 weeks, increase to 5 mg once weekly. Further increases may be made by 2.5 mg after at least 4 weeks on the current dose.

For chronic weight management, the recommended maintenance doses are 5 mg, 10 mg, or 15 mg once weekly. The maximum recommended dose is 15 mg once weekly.

See the current Zepbound Prescribing Information and the FDA weight-management approval announcement.

Zepbound Dosage for Obstructive Sleep Apnea

For adults with obesity and moderate to severe obstructive sleep apnea, Zepbound follows the same 2.5 mg starting dose and gradual escalation. The recommended maintenance dose for OSA is 10 mg or 15 mg once weekly.

FDA approved this indication in December 2024; see the FDA OSA approval announcement.

How Fast Can the Tirzepatide Dose Be Increased?

Both current labels require at least 4 weeks on the current dose before another 2.5 mg increase. The gradual escalation is intended to reduce gastrointestinal adverse reactions. Dose increases should follow the relevant indication and the prescribing clinician's assessment of response and tolerability.

What If You Miss a Tirzepatide Dose?

For both Mounjaro and Zepbound, take a missed dose as soon as possible if it is within 4 days (96 hours) of the scheduled dose. If more than 4 days have passed, skip the missed dose and take the next dose on the regularly scheduled day.

The weekly dosing day can be changed if at least 3 days (72 hours) separate the two doses. Do not take doses closer together than directed.

See the missed-dose sections of the Mounjaro label and Zepbound label.

Tirzepatide Dosage in Units: Why There Is No Universal Conversion

Mounjaro and Zepbound doses are prescribed in milligrams, not universal syringe units. A units-based chart can be unsafe because the number of syringe units needed for a milligram dose depends on the concentration and volume of the specific product.

This is especially important with compounded tirzepatide, where concentrations and dispensing devices may vary. Do not convert a prescribed milligram dose into syringe units using a chart from another pharmacy, website, or product. Follow the exact label and pharmacy instructions for the product dispensed to you.

Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality. See FDA's compounding questions and answers.

Special Populations and Dose Adjustment

Renal Impairment

No routine Mounjaro dose adjustment is recommended for renal impairment, including end-stage renal disease. Tirzepatide pharmacokinetics were not meaningfully changed by renal impairment. Renal function may need monitoring if nausea, vomiting, or diarrhea causes significant dehydration, particularly during treatment initiation or escalation.

Hepatic Impairment

No routine Mounjaro dose adjustment is recommended for hepatic impairment. The current Mounjaro label and a dedicated hepatic pharmacokinetic study found no clinically meaningful change in tirzepatide exposure across hepatic impairment groups.

Older Adults

Age alone does not create a separate dosing schedule. The current Mounjaro label reports no overall differences in safety or effectiveness between adults age 65 years and older and younger adults.

Side Effects During Dose Escalation

The most common tirzepatide adverse effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia. These reactions often occur during dose escalation, which is one reason the dose is increased gradually.

There is no reliable universal rule that a specific strength such as 7.5 mg or 12.5 mg will cause a certain side effect or that symptoms will resolve within a fixed number of days. If adverse effects are severe, persistent, or interfere with hydration or nutrition, contact the prescribing clinician before increasing the dose.

Tirzepatide also carries a boxed warning about thyroid C-cell tumors observed in rats and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Serious warnings also include pancreatitis, severe gastrointestinal reactions, gallbladder disease, hypersensitivity, and dehydration-related kidney injury.

Disclaimer

Disclaimer: This website connects patients with licensed healthcare providers who can evaluate medical conditions and prescribe medications when appropriate. Some medications available through this service may be compounded drugs, which are customized formulations prepared by a pharmacy. The FDA does not conduct premarket review for compounded drugs to evaluate their safety, effectiveness, or quality. (See here: https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved). Individual results may vary, and these medications should only be used under the guidance of a qualified healthcare professional. The information in this article is for educational purposes only and should not be considered medical advice. Always consult your healthcare provider before starting any new treatment.